Clinical Trials

Trial Open: Relief for Dry Mouth (Xerostomia)

We are promoting the AQUAx2 Study, an important clinical trial for patients experiencing persistent dry mouth (xerostomia) following radiotherapy for Head & Neck cancers. Xerostomia significantly impacts quality of life, and this trial is investigating a gene therapy designed to alleviate those symptoms.

• What it is: A Phase II trial investigating a gene therapy (Aquaporin-1) delivered directly to the salivary glands.

• Why it matters: This research is innovative and offers potential hope for long-term symptom relief.

If you or someone you know is suffering from radiotherapy-induced dry mouth, we encourage you to check the eligibility criteria and learn more about the AQUAx2 Study..

Join the trial PRONTO!

We are excited to announce that the pivotal PRONTO trial is officially open for recruitment at The Christie and UCLH, representing a significant step forward in optimising care for Salivary Gland Cancer.

PRONTO is an evaluative study investigating the role of Proton Beam Radiotherapy (PBT) as an adjuvant treatment for patients with localised parotid carcinoma, the most common site for SGC.

Crucially, the primary focus of this study is on patient quality of life: specifically, evaluating whether PBT can significantly reduce the incidence of long-term taste disturbance compared to conventional X-ray radiotherapy.

Any radiotherapy department in England and Wales can now refer eligible patients via the NHS Proton Referral Portal, and we encourage both patients and clinicians to learn more about this vital research aimed at improving survivorship.